STAAR Surgical Celebrates Two Million Lens Milestone for Implantable Collamer® Lens (ICL)

Milestone Follows U.S. FDA Approval of EVO Visian® ICL in March EVO Offers Visual Freedom from Glasses and Contact Lenses LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that more than two million Visian® Implantable Collamer lenses … [Read more…]

Study Shows Significantly Reduced Airborne Bacteria in Urgent Care Outpatient Facility Using WellAir’s Defend 400

Rooms using the device showed a 52% reduced total bacterial count over a 5-day period, including a 60% reduction in opportunistic pathogens STAMFORD, Conn.–(BUSINESS WIRE)–WellAir, a leading provider of indoor air disinfection and purification solutions, today released real-world test results demonstrating how its Defend 400 device reduced airborne bacteria at an urgent care outpatient facility … [Read more…]

Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection

– ECOSPOR IV study shows favorable safety profile through 24-week follow-up, consistent with the safety profile observed in ECOSPOR III study – 91.3% sustained clinical response achieved at eight weeks in overall population with consistent results in key subpopulations including first recurrence – – Rolling Biologics License Application (BLA) submission initiated and on track for … [Read more…]

Alzheon to Present ALZ-801 (Valiltramiprosate) Oral Tablet Program Update as Potential Treatment for Alzheimer’s Disease in Adults with Down Syndrome at 4th International Trisomy 21 Research Conference

New Results Position ALZ-801 to Potentially Become the First Oral Agent that Can Slow or Even Stop and Prevent Alzheimer’s Pathology in Patients and Healthy Individuals at Risk for the Disease Significant Effects of ALZ-801 on Beta Amyloid and Tau Biomarkers in Patients with Alzheimer’s Support its Clinical Development in Genetically Determined Disorders of Brain … [Read more…]

Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test

BOULDER, Colo.–(BUSINESS WIRE)–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced that WPS Government Health Administrators, the Medicare Administrative Contractor with jurisdiction for Biodesix’s De Soto, Kansas laboratory, has provided coverage for the Nodify CDT® lung nodule test. The Nodify CDT test is a part of the … [Read more…]

RARE-X Releases New Report that Uncovers Large Number of Previously Uncounted Rare Diseases

–             The “Power of Being Counted” Report reveals previously severely undercounted numbers used for decades to define rare diseases and help shape policies and biomedical discovery –       Study provides critical data to global researchers, clinicians, drug developers and patient advocates in their mission to improve outcomes for patients WASHINGTON–(BUSINESS WIRE)–RARE-X, a nonprofit organization dedicated to … [Read more…]

ECP Pharma’s Path Forward Clearer After FDA’s Response To Pre-IND Submission On Its Neurological, CNS Diseases Drug Products

MIAMI–(BUSINESS WIRE)–ECP Pharma has received a favorable, positive written response from the FDA regarding its Pre-IND submission of novel drugs for targeted indications with no clinically proven treatment options using underutilized APIs (Active Pharmaceutical Ingredients). The FDA provided a clear order of when clinical studies should be conducted by ECP Pharma, which increases the likelihood … [Read more…]

$200+ Billion Cancer Diagnostics Markets by Test, Technology, Application, End User, & By Region – Global Forecast and Analysis 2022-2027 –

DUBLIN–(BUSINESS WIRE)–The “Global Cancer Diagnostics Market, By Test, Technology, Application, End User, & By Region – Forecast and Analysis 2022-2027” report has been added to’s offering. The global cancer diagnostics market was valued at USD 128.30 Billion in 2021, and it is expected to reach a value of USD 203.60 Billion by 2027, at … [Read more…]

Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces, that the initiation of a Proof of Concept (POC) clinical trial of SENS-401 (Arazasetron) in patients scheduled for cochlear implantation … [Read more…]

Genexine reports encouraging top-line results of the Phase 1b/2 clinical trial with GX-I7 (efineptakin alfa) in refractory or recurrent (R/R) metastatic Triple Negative Breast Cancer

SEOUL, South Korea–(BUSINESS WIRE)–Genexine (KOSDAQ: 095700) a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced top-line results from the KEYNOTE-899 phase 1b/2 clinical trial of GX-I7 (efineptakin alfa) in combination with pembrolizumab. The results indicated that GX-I7 in combination … [Read more…]